Dr. Noah Biotech is a company dedicated to developing rare
disease combinations using the AI system. It was selected as an SME venture
enterprise for innovation growth support project.
This project identifies promising start-ups and venture
companies in the field of BIG 3 and grants up to 1.2 billion won for the
commercialization or R&D funding, or up to 13 billion won per selected
company for the policy funding or technology financing.
Dr. Noah Biotech is focusing on developing its own treatment
for neurological and muscular diseases by utilizing artificial intelligence
technology in the world's first compound design system. It prioritizes the technology
transfer of the newly discovered compounds after pre-clinical or phase 1 clinical
tests. Currently, many domestic and foreign pharmaceutical companies are not providing
simple analysis services but are carrying out new drug development projects
only for the models that are jointly invested and jointly developed.
Furthermore, Dr. Noah Biotech is employing the ARK system, an
artificial intelligence-based compound prediction platform. The ARK system is
designed to comprehensively analyze patients' genomic data/network/3D
structure/literature information to recommend optimal drugs for patients by
rank, all of which are completed within three months. It is also designed to
predict up to double and triple compounds, as well as a single drug.
Dr. Noah Biotech has developed and is operating on an
artificial intelligence technology, but the keywords of its business are "compound"
and "rare diseases." Its goal is to develop rare disease treatments
faster and more efficiently than anyone else by combining existing drugs into
new compounds. To achieve this goal, ARK, an original AI-based compound
prediction system, has been developed and is expanding its own new compound